Powerful Medical

What Powerful Medical does

Powerful Medical is a private medical technology company founded in 2017 in Slovakia with dual legal entities (POWERFUL MEDICAL s.r.o. in Bratislava and POWERFUL MEDICAL Inc. in New York). The company develops PMcardio, an AI-powered platform that interprets 12-lead ECGs to detect cardiovascular conditions, including the Queen of Hearts model for acute STEMI/STEMI-equivalent detection (FDA Breakthrough Device Designation) and LVsense for reduced left ventricular ejection fraction detection. The core technology consists of deep neural networks trained on 4 million+ clinically labeled ECGs matched to patient outcomes, deployed as a CE-marked Class IIb medical device under EU MDR with multiple ISO, SOC 2, and HIPAA certifications.

The platform is delivered through three go-to-market motions: a Freemium mobile app for individual clinicians (free 5 ECGs/month with Pro subscription upgrade, distributed via Apple App Store and Google Play Store with 100,000+ clinician users); an enterprise platform for hospitals and health systems (PMcardio for Organizations, featuring team management, EHR/device integrations, and real-time alerting, deployed across 150+ hospitals); and OEM licensing (notably integration with Roche's cobas pulse point-of-care platform announced August 2025). Five clinical suites extend the platform into acute care, echo screening, remote monitoring, patient-facing wearables, and angiography analysis.

The company has raised approximately $69.21 million in total disclosed funding (Crunchbase) including a $9.5M round in 2022, a $2.7M EIC Accelerator round in February 2024, and a €40M non-dilutive IPCEI grant from the European Commission in July 2025. The Scientific Board comprises 28 world-class cardiologists, and the AI has been validated in 25+ peer-reviewed studies across U.S. and European health systems including Mayo Clinic, Duke Health, Washington University, Mount Sinai Morningside, Hennepin County Medical Center, and Cardiovascular Centre Aalst. The company operates globally across EMEA, the Americas, and the Middle East with an interdisciplinary team of 51-100 employees spanning physicians, data scientists, AI experts, software engineers, regulatory specialists, and commercial functions.

Name

Powerful Medical

Legal name

POWERFUL MEDICAL s.r.o.

Website

https://powerfulmedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Powerful Medical develops PMcardio, a CE-marked AI platform that interprets 12-lead ECGs to detect 50+ cardiovascular conditions, serving 100,000+ clinicians and 150+ hospitals globally through a freemium mobile app, enterprise deployments, and OEM partnerships.

Ownership category

akta.pro rank

Product category

AI ECG Interpretation and Cardiac Diagnostics Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

akta.pro secondary industries

Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiology Telemedicine Platforms (HLALAGAB), Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI)

Keywords

• AI ECG interpretation
• Cardiac diagnostics software
• Cardiovascular AI platform
• Medical imaging AI
• Clinical decision support

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. PMcardio for Individuals (Freemium + Subscription): Free plan offering up to 5 ECGs per month. Paid Pro subscription provides larger monthly ECG quota, AI explainability for STEMI, 12 validated interval measurements, and 30-day report history. Revenue generated from individual clinician subscriptions.
2. PMcardio for Organizations (Enterprise Subscription): Team and enterprise plans with institution-wide ECG access, admin dashboard, device & EHR integrations, and real-time alerting. Sold to hospitals and health systems through direct sales and demos.
3. Technology Integration / OEM Licensing: Integration of PMcardio AI ECG interpretation into third-party platforms such as Roche cobas pulse point-of-care platform, generating licensing/technology fees.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Powerful Medical develops PMcardio, a CE-certified AI-powered ECG interpretation platform that reads 12-lead ECGs and detects 50+ cardiac conditions including STEMI, OMI, arrhythmias, conduction disorders, and reduced LVEF. The platform is offered as PMcardio for Individuals (mobile app with freemium and Pro subscription tiers for healthcare professionals) and PMcardio for Organizations (enterprise cardiac care coordination platform with team management, device/EHR integrations, and real-time alerting for hospitals and health systems).

Product overview

Powerful Medical offers PMcardio as a unified AI-powered ECG interpretation platform with a platform-plus-modules architecture. The core PMcardio Platform provides instant cardiovascular diagnostics through AI models trained on 4 million+ ECGs. Two product variants serve different segments: PMcardio for Individuals (mobile app with AI second-opinion capabilities) and PMcardio for Organizations (enterprise cardiac care coordination with team management and real-time alerting). Key AI modules include PMcardio STEMI AI (Queen of Hearts) for STEMI/OMI detection, PMcardio LVEF AI (LVsense) for reduced ejection fraction detection, and ECGxplain for AI explainability. Five clinical suites extend the platform: Acute Care Suite (emergency cardiac events), Echo Screening Suite (structural heart disease), Remote Monitoring Suite (ambulatory recordings), Patient Suite (consumer wearables), and Angio Suite (coronary angiography analysis). The platform is CE-marked under EU MDR and has received FDA Breakthrough Device Designation.

Differentiator

Problem solved

Functional benefit

Brands

• PMcardio: AI-powered ECG interpretation platform that analyzes 12-lead ECGs to detect 50+ cardiac conditions including STEMI, OMI, arrhythmias, and conduction disorders. Available as PMcardio for Individuals and PMcardio for Organizations.
• Queen of Hearts
• LVsense
• ECGxplain

Products and services

• PMcardio Platform Unified AI-powered ECG interpretation platform that brings instant cardiovascular diagnostics to clinicians and health systems, supporting the full spectrum of cardiac care from acute emergency detection to longitudinal monitoring. Accepts any 12-lead ECG image via smartphone capture or upload.
• PMcardio for Individuals Mobile app providing instant AI-powered ECG interpretations as a second opinion tool for individual healthcare professionals. Includes Queen of Hearts STEMI/OMI detection, LVsense reduced LVEF detection, ECGxplain explainability heatmaps, and detection of 36 core diagnoses including arrhythmias and conduction blocks. Distributed via Apple App Store and Google Play Store with a freemium model (5 free ECGs/month) and Pro subscription upgrade path.
• PMcardio for Organizations Enterprise cardiac care coordination platform enabling institution-wide ECG access, team management, device and EHR integrations, and real-time alerting. Designed for hospitals, EMS, and health systems at scale with no per-seat limits; sold via enterprise direct sales and demos.
• PMcardio STEMI AI (Queen of Hearts) AI ECG model for detecting acute ST-elevation myocardial infarction (STEMI) and STEMI-equivalent patterns including subtle occlusions without ST elevation. FDA Breakthrough Device Designation. Detects up to 39 cardiac conditions including hidden heart attacks standard criteria miss. CE-marked medical device under EU MDR.
• PMcardio LVEF AI (LVsense)

Quantifiable outcome

• Up to 2x higher sensitivity for detecting heart attacks vs. standard of care
• +11 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature8 records

Partnerships

Nine partnerships are on record, tiered core and flagship.

• RochecoreTechnology or Integration · 21 August 2025Powerful Medical announced a collaboration with Roche to integrate PMcardio's AI ECG interpretation and Roche's high-sensitivity cardiac Troponin T testing into the cobas pulse point-of-care platform, aimed at improving heart attack diagnosis at the bedside.
• AlphaiotacoreChannel Partner/ Reseller/ Distributor · 26 June 2025Alphaiota, a Saudi-based technology company, expanded its partnership with PMcardio to launch the first AI-powered heart attack diagnostic platform in Saudi Arabia. PMcardio detects 39 cardiac conditions and identifies heart attacks up to three hours earlier. Partnership aligns with Saudi Arabia's digital health goals.
• Mayo ClinicflagshipStrategic or Co-development Partner · 11 November 2024Mayo Clinic is listed as a partner institution for the PMcardio External Clinical Research Program, collaborating on clinical validation of AI ECG models.
• Duke HealthflagshipStrategic or Co-development Partner · 11 November 2024Duke Health is a partner institution for PMcardio's External Clinical Research Program, contributing to clinical validation studies.
• Washington University in St. LouisflagshipStrategic or Co-development Partner · 11 November 2024Washington University in St. Louis collaborated with PMcardio on evaluating the AI model for predicting occlusion myocardial infarction (OMI), demonstrating the AI's ability to identify OMI cases missed by standard ECG and reduce false-positive cath lab activations.
• Hennepin County Medical CenterflagshipStrategic or Co-development Partner · 11 November 2024Hennepin County Medical Center collaborated on multiple PMcardio validation studies, including prehospital ECG interpretation showing 34% reduction in false cath lab activations.
• Cardiovascular Center Aalst (Belgium)flagshipStrategic or Co-development Partner · 11 November 2024Cardiovascular Centre Aalst in Belgium collaborated with PMcardio on multiple validation studies, including demonstrating 68% reduction in false positive STEMI alerts and 34% reduction in ECG to balloon time.
• Mount Sinai MorningsideflagshipStrategic or Co-development Partner · 11 November 2024Mount Sinai Morningside performed retrospective validation of PMcardio STEMI AI ECG Model, demonstrating 81% sensitivity and 87% specificity in identifying high-risk patients with occlusion myocardial infarction.
• National Amosov Institute of Cardiovascular Surgery (Ukraine)coreStrategic or Co-development Partner · 11 November 2024National Amosov Institute of Cardiovascular Surgery evaluated PMcardio AI ECG model for detecting myocardial infarction in NSTEMI patients, achieving 85.3% accuracy.

Scale indicators12 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• iRhythm Technologies: iRhythm's Zio long-term cardiac patch and AI-driven arrhythmia detection compete with PMcardio's Remote Monitoring Suite in ambulatory ECG interpretation. Both target cardiologists and electrophysiologists with AI-augmented monitoring services.
• AliveCor: AliveCor markets FDA-cleared KardiaMobile/Kardia devices and AI for consumer and clinician ECG interpretation. Directly competes with PMcardio on AI-driven single-lead and 12-lead ECG analysis, especially in the US where AliveCor already has cleared devices and reimbursement.
• Eko Health: Eko combines digital stethoscopes with AI cardiac analysis (including ECG and murmur detection), serving clinicians and health systems. Directly comparable to PMcardio's AI-ECG-in-clinic positioning and overlapping clinician personas.

Others

• Tempus Labs: Tempus applies AI across clinical and molecular data. Adjacent peer—uses similar AI infrastructure for healthcare but is broader in scope, not a direct ECG competitor.

Emerging players

• Idoven: Idoven provides AI ECG analysis as a service to pharma, medical devices, and clinicians with a focus on arrhythmia and cardiac safety. Comparable European AI ECG peer with overlap in ECG-as-a-service and clinical validation.
• HeartFlow: HeartFlow applies AI to cardiac imaging (FFR-CT) for coronary disease assessment. While focused on CT rather than ECG, it competes with PMcardio in AI-driven cardiac diagnostics and shares the same cardiology buyer and CAD/MI pathway.
• Cleerly: Cleerly uses AI on CCTA imaging to characterize coronary plaque and stenosis. Comparable to PMcardio's Angio Suite in addressing cardiology diagnostic decision-making around coronary artery disease.
• Viz.ai: Viz.ai provides AI-driven clinical workflow and triage alerts (stroke and cardiology). Comparable to PMcardio's care-coordination, real-time alerting, and cath-lab activation use cases in time-critical cardiac care.

Broad incumbents

• GE HealthCare: GE HealthCare sells ECG machines, patient monitors, and AI analytics (Edison platform) that include AI-driven ECG interpretation. As a broad incumbent, it overlaps with PMcardio across hospital cardiology, acute care, and remote monitoring.
• Cardiologs (Philips): Acquired by Philips in 2021, Cardiologs provides AI ECG interpretation as part of Philips' broader cardiac monitoring portfolio. Competes with PMcardio's ECG analysis capabilities but bundled inside a large incumbent's device and informatics ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/powerfulmedical
• LinkedInlinkedin.com/company/powerful-medical
• Instagraminstagram.com/powerfulmedical
• Xx.com/PowerfulMedical

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Powerful Medical